Cancer biomarkers : section A of Disease markers最新文献

The impact of HER2 low positivity in hormone receptor-positive, HER2-negative breast cancer treated with neoadjuvant chemotherapy. HER2低阳性对激素受体阳性和HER2阴性乳腺癌新辅助化疗的影响

IF 1.9

Cancer biomarkers : section A of Disease markers Pub Date : 2026-01-01 Epub Date: 2026-02-25 DOI: 10.1177/18758592261427515

Mustafa Ersoy

{"title":"The impact of HER2 low positivity in hormone receptor-positive, HER2-negative breast cancer treated with neoadjuvant chemotherapy.","authors":"Mustafa Ersoy","doi":"10.1177/18758592261427515","DOIUrl":"10.1177/18758592261427515","url":null,"abstract":"AimsThis study aimed to investigate whether the efficacy of neoadjuvant chemotherapy differs between HER2-low and HER2-zero subgroups in hormone receptor-positive, HER2-negative breast cancer.Materials and MethodsA total of 61 patients who received neoadjuvant chemotherapy between 2015 and 2025 were retrospectively analyzed. HER2 status was determined from pre-treatment core biopsy specimens and classified as HER2-low (IHC 1 + or 2 + and FISH-negative) or HER2-zero (IHC 0). The pathological complete response (pCR) rates were compared between the two groups.ResultsAmong 61 patients, 28 had HER2-low and 33 had HER2-zero tumors. The pCR rate was 7.1% in the HER2-low group and 27.3% in the HER2-zero group (p = 0.042). A post-hoc power analysis based on these results showed a moderate power (0.59) to detect the observed difference.ConclusionsHER2-low expression may negatively influence chemosensitivity in hormone receptor-positive breast cancer treated with neoadjuvant chemotherapy. Further studies are warranted to evaluate the potential role of trastuzumab deruxtecan (T-DXd) and other antibody-drug conjugates in this newly defined subgroup.","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":"43 ","pages":"18758592261427515"},"PeriodicalIF":1.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13055881/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147286861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Detection of methylated SEPT9 DNA in peripheral blood for diagnosis of colorectal cancer. 外周血甲基化SEPT9 DNA检测对结直肠癌的诊断价值。

IF 1.9

Cancer biomarkers : section A of Disease markers Pub Date : 2026-01-01 Epub Date: 2026-05-07 DOI: 10.1177/18758592261449027

Mengjie Lin, Hong Chen, Caifeng Jiang

{"title":"Detection of methylated SEPT9 DNA in peripheral blood for diagnosis of colorectal cancer.","authors":"Mengjie Lin, Hong Chen, Caifeng Jiang","doi":"10.1177/18758592261449027","DOIUrl":"https://doi.org/10.1177/18758592261449027","url":null,"abstract":"BackgroundColorectal cancer (CRC) remains a leading cause of cancer-related death worldwide. Although colonoscopy is effective screening method, its widespread adoption is hampered by poor compliance. Development of patient-friendly screening methods that are minimally invasive is of paramount importance to improve CRC screening participation.MethodsA single-center case-control study was conducted. Blood samples were collected from 119 participants (79 CRC patients, 20 patients with colorectal adenomas, and 20 healthy colonoscopy-negative controls) during May 2023 and March 2025. The methylated SEPT9 (mSEPT9) DNA in peripheral blood was analyzed by droplet digital polymerase chain reaction (ddPCR).ResultsThe sensitivity and specificity of mSEPT9 detection in peripheral blood for diagnosis of all stages of CRC patients was 68.35% and 95.00%, respectively. The positive rate were similar between left-sided CRC and right-sided CRC (65.31% vs 72.41%，p ＞ 0.05). mSEPT9 detection in all healthy people with normal colonoscopy were negative. When mSEPT9 detection was combined with CEA and CA199, positive rate could be raised to 82.67%.ConclusionsBlood-based mSEPT9 detection by ddPCR method is a sensitive and specific method for non-invasive diagnosis of CRC. Combination with CEA and CA19-9 could improve its performance. It may serve as a viable alternative for individuals unwilling or unable to undergo invasive procedures.","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":"43 ","pages":"18758592261449027"},"PeriodicalIF":1.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147848881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Integrative bioinformatics analysis identifies HCCS as a prognostic and therapeutic biomarker in lung cancer. 综合生物信息学分析确定HCCS是肺癌的预后和治疗生物标志物。

IF 1.9

Cancer biomarkers : section A of Disease markers Pub Date : 2026-01-01 Epub Date: 2026-03-26 DOI: 10.1177/18758592261429264

Sm Faysal Bellah, Md Alim Hossen, S M Saker Billah

{"title":"Integrative bioinformatics analysis identifies HCCS as a prognostic and therapeutic biomarker in lung cancer.","authors":"Sm Faysal Bellah, Md Alim Hossen, S M Saker Billah","doi":"10.1177/18758592261429264","DOIUrl":"10.1177/18758592261429264","url":null,"abstract":"BackgroundLung cancer remains one of the leading causes of cancer-related mortality worldwide. Holocytochrome c synthase (HCCS), a mitochondrial enzyme involved in apoptosis and energy metabolism, has been implicated in tumorigenesis; however, its role in lung cancer is not well defined.AimThis study aimed to elucidate the prognostic and therapeutic potential of HCCS in lung cancer through integrative bioinformatics analyses.MethodsTranscriptomic, methylation, and clinical data from TCGA were analyzed using TNMplot, UALCAN, and TIMER2.0 to evaluate HCCS expression, promoter methylation, immune infiltration, and prognostic relevance in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC). Meta-analysis of 18 independent cohorts from LUNG CANCER EXPLORER and four GEO datasets validated expression patterns, while Kaplan-Meier analysis assessed survival outcomes.ResultsHCCS was significantly upregulated in LUAD and LUSC and showed promoter hypermethylation in LUAD. Meta-analysis and external validation confirmed its overexpression. Patients with low HCCS expression exhibited poorer overall survival, suggesting a potential tumor-suppressive effect. HCCS expression positively correlated with immune cell infiltration and co-expressed genes enriched in mitochondrial and apoptotic pathways.ConclusionHCCS may serve as a prognostic and therapeutic biomarker in lung cancer, linking mitochondrial regulation, epigenetic modification, and immune interactions.","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":"43 ","pages":"18758592261429264"},"PeriodicalIF":1.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13068008/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147518041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bidirectional Mendelian randomization analysis reveals significant associations between Serum DNA repair proteins and liver cancer. 双向孟德尔随机化分析揭示了血清DNA修复蛋白与肝癌之间的显著关联。

IF 1.9

Cancer biomarkers : section A of Disease markers Pub Date : 2026-01-01 Epub Date: 2026-04-22 DOI: 10.1177/18758592261429328

Sihao Lin, Kunpeng Fang, Li Geng

{"title":"Bidirectional Mendelian randomization analysis reveals significant associations between Serum DNA repair proteins and liver cancer.","authors":"Sihao Lin, Kunpeng Fang, Li Geng","doi":"10.1177/18758592261429328","DOIUrl":"https://doi.org/10.1177/18758592261429328","url":null,"abstract":"PurposeThis study investigated causal relationships and underlying mechanisms between serum DNA repair proteins and liver cancer to identify biomarkers for clinical management.MethodsA two-sample bidirectional Mendelian randomization (MR) design was employed. We performed inverse variance weighted (IVW) analysis, followed by protein quantitative trait loci (pQTL), colocalization, and pathway enrichment analyses to explore biological mechanisms.ResultsMR analysis revealed significant associations: NBR1 (IVW: OR = 2.28, 95%CI: 1.17-4.45, P = 0.015) and RAD51 (IVW: OR = 2.16, 95%CI: 1.12-4.15, P = 0.021) were risk factors. PARP11 was protective for hepatocellular carcinoma (OR = 0.48, 95%CI: 0.25-0.93, P = 0.030) but a risk for intrahepatic cholangiocarcinoma (OR = 1.86, 95%CI: 1.04-3.33, P = 0.038). Mechanistically, pQTL and colocalization identified rs2793568 as a key regulator of PARP1, which was enriched in base excision repair pathways. Sensitivity analyses confirmed the robustness of these findings.ConclusionSerum NBR1, RAD51, and PARP11 are potentially causal in liver cancer pathogenesis. Specifically, the genetic regulation of PARP1 highlights a critical DNA repair mechanism, supporting their utility as predictive biomarkers.","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":"43 ","pages":"18758592261429328"},"PeriodicalIF":1.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147795033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A panel of plasma proteins associated with venous thromboembolism in patients with prostate cancer. 一组血浆蛋白与前列腺癌患者静脉血栓栓塞相关。

IF 1.9

Cancer biomarkers : section A of Disease markers Pub Date : 2025-12-01 Epub Date: 2025-12-05 DOI: 10.1177/18758592251390251

Asha Jose, Simon Lu, Chao Zhang, Jennifer La, Melissa Young, J Michael Gaziano, Nathanael R Fillmore, Katya Ravid, Vipul C Chitalia

{"title":"A panel of plasma proteins associated with venous thromboembolism in patients with prostate cancer.","authors":"Asha Jose, Simon Lu, Chao Zhang, Jennifer La, Melissa Young, J Michael Gaziano, Nathanael R Fillmore, Katya Ravid, Vipul C Chitalia","doi":"10.1177/18758592251390251","DOIUrl":"10.1177/18758592251390251","url":null,"abstract":"PurposeVenous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, is a leading cause of morbidity and mortality in cancer patients. Prostate cancer is associated with an elevated risk of VTE, yet the molecular drivers remain poorly defined.MethodsIn this study, we employed high-throughput proteomic profiling using the SomaLogic platform to analyze plasma from 85 prostate cancer patients, including 43 with and 42 without VTE. Samples were collected at cancer diagnosis, with VTE diagnosed at a mean of 96.8 months later.ResultsPrincipal component analysis showed modest proteomic separation between groups. Differential expression analysis identified enriched pathways in VTE patients, including hemostasis (TIMP1, JAM2, TMX3, F3, and ESAM), cell adhesion (CXCL12, CCL11, CCN5, COL18A1, and ADGRB1) and cell proliferation (TIMP1, REG1B, REG1A, CRLF2, and ALDH1A2). Receiver Operating Characteristic analysis using top fifteen proteins achieved an area under the curve of 0.859, indicating strong predictive value for VTE in this cohort.ConclusionsWe identified a specific cluster of circulating proteins associated with development of VTE in patients with prostate cancer. This work deepens understanding of systemic mediators of cancer-associated VTE and, pending validation in other cohorts, paves the way for improved risk stratification and long-term monitoring in this population.","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":"42 12","pages":"18758592251390251"},"PeriodicalIF":1.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13085878/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145688946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Characterization of a novel four-miRNA signature in papillary thyroid carcinoma: Integrating molecular profiling, hormonal regulation, and diagnostic implications in populations with rising PTC incidence. 甲状腺乳头状癌中一种新型4 - mirna特征的表征：整合分子分析、激素调节和PTC发病率上升人群的诊断意义

IF 1.9

Cancer biomarkers : section A of Disease markers Pub Date : 2025-11-01 Epub Date: 2025-11-04 DOI: 10.1177/18758592251392827

Afshan Afzal, Nafeesa Kainat, Aayesha Riaz, Afia Malik, Azhar Ejaz, Yasmeen Sher, Zaineb Tariq, Kainat Abbasi, Rashida Khan, Ruqia Mehmood Baig

{"title":"Characterization of a novel four-miRNA signature in papillary thyroid carcinoma: Integrating molecular profiling, hormonal regulation, and diagnostic implications in populations with rising PTC incidence.","authors":"Afshan Afzal, Nafeesa Kainat, Aayesha Riaz, Afia Malik, Azhar Ejaz, Yasmeen Sher, Zaineb Tariq, Kainat Abbasi, Rashida Khan, Ruqia Mehmood Baig","doi":"10.1177/18758592251392827","DOIUrl":"https://doi.org/10.1177/18758592251392827","url":null,"abstract":"Diagnosing papillary thyroid carcinoma (PTC) remains challenging, particularly due to limitations in fine-needle aspiration biopsy (FNAB), which yields up to 10% nondiagnostic results. The objective of this study was to evaluate the diagnostic and prognostic potential of four candidate microRNAs (miR-21, miR-31, miR-187-3p, and miR-200a-5p) in PTC from multinodular goiter (MNG) and normal. Fresh tissue samples from PTC and MNG patients were analyzed using quantitative RT-PCR, followed by ROC analysis to assess diagnostic accuracy and correlation with clinical, histopathological, and hormonal parameters. Compared to normal tissue, miR-21 and miR-187-3p were significantly upregulated in PTC, while miR-31 and miR-200a-5p were downregulated. MNG samples showed similar but less pronounced trends. All four miRNAs differed significantly between PTC and MNG. ROC analysis revealed strong diagnostic performance, particularly for miR-187-3p (AUC = 0.937) and miR-21 (AUC = 0.914), with their combination achieving an AUC of 0.968. Expression levels correlated with age, tumor stage, surgical status, and thyroid hormones (TSH, ATG, TG), highlighting novel regulatory patterns. This miRNA panel offers promising diagnostic value and insight into PTC pathogenesis, suggesting potential for non-invasive diagnostics and targeted therapies.","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":"42 11","pages":"18758592251392827"},"PeriodicalIF":1.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145440402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CD137L and colorectal cancer prognosis: Insights from clinical and TCGA data analysis. CD137L与结直肠癌预后：来自临床和TCGA数据分析的见解

IF 1.9

Cancer biomarkers : section A of Disease markers Pub Date : 2025-11-01 Epub Date: 2025-11-05 DOI: 10.1177/18758592251375149

Kaiyu Xu

{"title":"CD137L and colorectal cancer prognosis: Insights from clinical and TCGA data analysis.","authors":"Kaiyu Xu","doi":"10.1177/18758592251375149","DOIUrl":"10.1177/18758592251375149","url":null,"abstract":"BackgroundCD137L plays a substantial role in immune regulation and has been associated with tumor progression. However, its expression pattern and clinical significance in colorectal cancer remain unclear. The current study was planned to evaluate the expression levels of CD137L in colorectal cancer tissues and investigate its association with clinicopathological characteristics and patient survival.Methodology36 tissue samples were collected from colorectal cancer patients followed by RNA extracted. Following the cDNA synthesis, qRT-PCR was conducted to evaluate the CD137L expression, normalized against GAPDH and the comparative expression was determined using the ΔΔCt method. Chi-square test was applied to evaluate the relation of CD137L expression with clinical parameters. Meanwhile, the TCGA database was explored to find the relationship between the prognosis of colorectal cancer patients and different levels of CD137L expression and to analyze the distribution characteristics of differentially expressed genes.ResultsCD137L expression was significantly correlated with patient survival (P < 0.05), with higher expression observed in patients who were alive at the time of analysis. Clinical parameters such as age and gender were insignificantly associated (P > 0.05) with CD137L expression. However, a significant correlation (P = 0.03) was noted between CD137L expression and tumor staging, suggesting its potential involvement in CRC progression. Furthermore, Analysis of TCGA data showed that patients with elevated CD137L expression exhibited improved overall survival compared to those with lower expression levels. Enrichment analysis revealed that CD137 was primarily enriched with immune cell proliferation, T cell activation and Th1/Th2 balance-related signaling pathways.ConclusionCD137L may serve as a reliable indicator for forecasting the outcome of colorectal cancer patients, providing guidance for colorectal cancer prognosis.","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":"42 11","pages":"18758592251375149"},"PeriodicalIF":1.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13085905/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145447026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Serum exosomal miR-1275 as a potential biomarker for the diagnosis and prognostic assessment of hepatocellular carcinoma. 血清外泌体miR-1275作为肝细胞癌诊断和预后评估的潜在生物标志物

IF 1.9

Cancer biomarkers : section A of Disease markers Pub Date : 2025-11-01 Epub Date: 2025-11-13 DOI: 10.1177/18758592251396221

Yang Jun, Chen Yeng, Shen Sainan, Xiao Jingwen, He Yu, Khalilah Binti Abdul Khalil, Maslinda Binti Musa

{"title":"Serum exosomal miR-1275 as a potential biomarker for the diagnosis and prognostic assessment of hepatocellular carcinoma.","authors":"Yang Jun, Chen Yeng, Shen Sainan, Xiao Jingwen, He Yu, Khalilah Binti Abdul Khalil, Maslinda Binti Musa","doi":"10.1177/18758592251396221","DOIUrl":"10.1177/18758592251396221","url":null,"abstract":"BackgroundHepatocellular carcinoma (HCC) is a major global health burden, with limited tools for early diagnosis and prognosis. This study explores serum-derived exosomal miR-1275 as a potential non-invasive biomarker for HCC.MethodsExosomes were isolated from serum samples of 50 HCC patients and 50 matched healthy controls. miR-1275 expression was quantified by qRT-PCR and compared with traditional biomarkers (AFP, CEA, CA199, DCP, AFP-L3%). Diagnostic performance was evaluated using ROC curves. Bioinformatic analyses, including TCGA pan-cancer data, target gene prediction, and pathway enrichment, were performed to explore regulatory mechanisms.ResultsExosomal miR-1275 levels were significantly reduced in HCC patients and correlated with advanced clinical stage, tumor burden, and metastasis. miR-1275 showed strong diagnostic value (AUC = 0.869), outperforming CEA and CA199, and improved significantly when combined with other biomarkers (AUC = 0.982). UBE2V1 was identified as a key miR-1275 target involved in cancer-related pathways, including ubiquitination and mTOR signaling.ConclusionSerum exosomal miR-1275 is a promising biomarker for early diagnosis and prognosis of HCC. Its integration into multimarker panels could enhance clinical decision-making and patient management.","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":"42 11","pages":"18758592251396221"},"PeriodicalIF":1.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13085904/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145515428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

TUBB3 (βIII-tubulin) drives gastric cancer progression and poor prognosis by regulating cell cycle and invadopodia formation. TUBB3 （β iii -微管蛋白）通过调节细胞周期和侵入足形成，驱动胃癌进展和不良预后。

IF 1.9

Cancer biomarkers : section A of Disease markers Pub Date : 2025-10-01 Epub Date: 2025-10-23 DOI: 10.1177/18758592251390145

Hui Ge, Hui Tang, Tingting You, Chunmei Bai, Zhao Sun, Qin Han, Robert Chunhua Zhao

{"title":"TUBB3 (βIII-tubulin) drives gastric cancer progression and poor prognosis by regulating cell cycle and invadopodia formation.","authors":"Hui Ge, Hui Tang, Tingting You, Chunmei Bai, Zhao Sun, Qin Han, Robert Chunhua Zhao","doi":"10.1177/18758592251390145","DOIUrl":"10.1177/18758592251390145","url":null,"abstract":"BackgroundGastric cancer is the fifth most common malignancy and third leading cause of cancer death in China, with advanced-stage five-year survival below 20%. βIII-tubulin (TUBB3) is overexpressed in cancers but its role in gastric cancer remains unclear.MethodsTUBB3 expression was analyzed using TCGA data and clinical samples. Knockdown models assessed its effects on proliferation, migration, and invasion in vitro and in vivo.ResultsTUBB3 was significantly upregulated in gastric cancer tissues versus normal mucosa. High TUBB3 correlated with poorer disease-free and overall survival but not other clinicopathological features. Functionally, TUBB3 knockdown inhibited proliferation via G2/M arrest and reduced migration/invasion by disrupting invadopodia, without affecting apoptosis, EMT, or ECM degradation. In vivo, TUBB3 depletion suppressed tumor growth and metastasis. Mechanistically, TUBB3 promoted G2/M transition via p21/Cyclin B1 and enhanced invasiveness through Cortactin/JNK activation.ConclusionTUBB3 overexpression predicts poor prognosis in gastric cancer. It drives proliferation via cell cycle regulation and metastasis through invadopodia formation, suggesting its potential as a therapeutic target.","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":"42 10","pages":"18758592251390145"},"PeriodicalIF":1.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13085911/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145357453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The overexpression of HOXC6 in LUSC and pan-squamous cell carcinomas indicates the coexistence of nuclear division regulatory mechanisms. HOXC6在LUSC和泛鳞状细胞癌中的过表达表明核分裂调控机制共存。

IF 1.9

Cancer biomarkers : section A of Disease markers Pub Date : 2025-10-01 Epub Date: 2025-10-29 DOI: 10.1177/18758592251390255

Shu-Jia He, Ke-Jun Wu, Yi-Yang Chen, Yan-Ting Zhan, Yu-Xing Tang, Xiao-Song Chen, Zhi-Guang Huang, Qi Li, Bin Li, Yong-Yao Gu, Gang Chen, Jin-Liang Kong, Feng Chen

{"title":"The overexpression of HOXC6 in LUSC and pan-squamous cell carcinomas indicates the coexistence of nuclear division regulatory mechanisms.","authors":"Shu-Jia He, Ke-Jun Wu, Yi-Yang Chen, Yan-Ting Zhan, Yu-Xing Tang, Xiao-Song Chen, Zhi-Guang Huang, Qi Li, Bin Li, Yong-Yao Gu, Gang Chen, Jin-Liang Kong, Feng Chen","doi":"10.1177/18758592251390255","DOIUrl":"10.1177/18758592251390255","url":null,"abstract":"BackgroundHomeobox C6 (HOXC6) shows abnormal expression in various tumors, but its pattern in lung squamous cell carcinoma (LUSC) remains unclear.ObjectiveTo investigate HOXC6's expression and function in LUSC.MethodsHOXC6 expression was analyzed using single-cell RNA sequencing (scRNA-seq) in LUSC, cervical squamous cell carcinoma (CESC), esophageal squamous cell carcinoma (ESCC), laryngeal squamous cell carcinoma (LSCC), and oral squamous cell carcinoma (OSCC), verified by RNA-seq and immunohistochemistry (IHC). CRISPR knockdown assessed proliferation impact. Immune infiltration analysis, single-sample Gene Set Enrichment Analysis (ssGSEA), Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data (ESTIMATE), Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses explored immune microenvironment relationships.ResultsHOXC6 was highly expressed in LUSC (standard mean difference (SMD) = 1.17, confidence interval (CI) = 0.75-1.59, area under the curve (AUC) = 0.88), confirmed by IHC (P = 1.6e-10, AUC = 0.99). HOXC6 silencing inhibited proliferation. High expression negatively correlated with immune infiltration and decreased StromalScore, ImmuneScore, and ESTIMATEScore. HOXC6 was elevated in other squamous carcinomas.ConclusionHigh HOXC6 expression may promote LUSC and pan-squamous carcinoma development through mitosis regulation.","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":"42 10","pages":"18758592251390255"},"PeriodicalIF":1.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13085907/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145403730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0